“My dentist told me that I need a root canal, but I have no pain, and I am wondering if I really need to do it?” Usually, the answer is yes, for several reasons. One could be that we caught the ...

David I. Quinn, MD, MBBS, PhD and other oncologists, discussed disease management and the option of using an osteoclast-targeting agent for a 75-year-old man with metastatic castration-resistant ...

Background: Maintenance treatment after autologous bone marrow transplantation in multiple myeloma improves the outcome of patients. We designed a phase II clinical trial to evaluate the treatment ...

A patient with multiple myeloma shares his story and how his oncology nurse has provided him with care and empathy on his cancer journey. First, an introduction: I am an 80-year-old patient who ...

Osteoporosis treatments were not linked with reduced overall mortality, according to a meta-analysis of placebo-controlled trial data. Looking at data from 38 clinical trials, there was no significant ...

Biotech major Amgen Inc.AMGN announced that the European Commission has approved its regulatory application, which was looking to expand the current indication for Xgeva for the prevention of skeletal ...

Phase III trial results presented at the 2014 ASCO Annual Meeting showed that the dosing frequency of zoledronic acid (Zometa) can be reduced by 67% without compromising effectiveness in women with ...

OptumInsight, Health Economics and Outcomes Research, Eden Prairie, MN, USA. Patients with bone metastases secondary to genitourinary (GU) cancer are at risk for skeletal-related events (SREs), ...

FDA is requiring the zoledronic acid (Reclast, Novartis) prescribing information to now include a warning not to use the drug in those with renal dysfunction. FDA is requiring the zoledronic acid ...